This book collects a number of essays on the origins, accomplishments, and aspirations of the ICN by leading competition agency officials, private sector lawyers, and academics. (Paul Lugard, ed.)

This contribution looks at why the ICN matters to competition agencies, businesses, consumers, and other participants in the international competition community. Sophie Mitchell (OFT)

With ICN practices now the industry standard, as it enters its second decade the ICN needs to carefully consider how it balances respect for diversity with its goal of promoting convergence. Maria Coppola (FTC)

The differing outcomes between the judges and jury reflect the difficult challenges remaining for the UCWG in building greater convergence among different jurisdictions in the analysis of loyalty discounts and rebates. Cynthia Lagdameo (FTC) & Charles Webb (Baker Botts)

Conformity with the jurisdictional nexus Recommended Practice was a focal point of advocacy throughout the development of the Indian merger control regime. Neil Campbell & Sorcha O’Carroll (McMillan & Co.)

Providing competition agencies with a much greater capacity to provide a coordinated response to globalized cartel activity. Marcus Bezzi (Australian Competition & Consumer Comm.) & József Sárai (Hungarian Competition Auth.)

The antitrust agencies are unlikely to challenge a clinical integration network that is able to generate significant efficiencies that benefit consumers and about which payers do not complain. Christi Braun, Ober Kaler

This discussion should help prospective ACOs understand how to pursue the benefits envisioned by the Affordable Care Act while avoiding antitrust concerns. Gregory Vistnes, CRA

This article explores how the DOJ and FTC have treated clinically-integrated managed care contracting networks under the antitrust laws, and how the Agencies are likely to apply those concepts to ACOs. Ashley Fischer & David Marx, Jr., McDermott Will & Emery

Are “clinically integrated†physician networks that jointly contract with third-party payors such as Blue Cross little more than “candy-coated†cartels? Gregory Pelnar, Compass Lexecon